Skip to search formSkip to main contentSkip to account menu

SU 11248

Known as: SU 011248, SU011248, SU11248 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Sunitinib (SU011248) is an oral small molecular tyrosine kinase inhibitor that exhibits potent antiangiogenic and antitumor… 
Highly Cited
2006
Highly Cited
2006
PURPOSE Renal cell carcinoma (RCC) is characterized by loss of von Hippel Lindau tumor suppressor gene activity, resulting in… 
Highly Cited
2006
Highly Cited
2006
PURPOSE To establish the safety, pharmacokinetics, and recommended dose of sunitinib, a novel oral multitargeting tyrosine kinase… 
Review
2006
Review
2006
Context Sunitinib, a tyrosine kinase inhibitor, has recently been approved for the treatment of gastrointestinal stromal tumors… 
Review
2005
Review
2005
Cancer chemotherapy has been one of the major medical advances in the last few decades. However, the drugs used for this therapy… 
Highly Cited
2005
Highly Cited
2005
Fifteen patients with refractory AML were treated in a phase 1 study with SU11248, an oral kinase inhibitor of fms-like tyrosine… 
Highly Cited
2003
Highly Cited
2003
One challenging aspect in the clinical development of molecularly targeted therapies, which represent a new and promising… 
Highly Cited
2003
Highly Cited
2003
FLT3 (fms-related tyrosine kinase/Flk2/Stk-2) is a receptor tyrosine kinase (RTK) primarily expressed on hematopoietic cells. In… 
Highly Cited
2003
Highly Cited
2003
The purpose of this study was to evaluate the activity of the indolinone kinase inhibitor SU11248 against the receptor tyrosine…